During his time in the FTC's Mergers I Division, David led investigations that resulted in groundbreaking actions against monopolist acquisitions of nascent competitors. In one case, the FTC challenged a pharmaceutical company's consummated acquisition of a pipeline Infantile Spasms drug under Section 2 of the Sherman Act, resulting in a settlement requiring a sublicense and $100 million in disgorgement — the largest equitable monetary relief ever secured by the government in a merger case. In another, the agency sued to block a DNA sequencing platform provider's acquisition of a differentiated rival platform, prompting the parties to abandon the transaction. David also shaped the legal framing of a recent FTC challenge to a pharmaceutical company's proposed acquisition of a preclinical-phase treatment for Pompe disease, which the parties then abandoned.
David played a pivotal role in the FTC's Illumina/Grail administrative trial and appeal, in which the agency challenged a DNA sequencing platform provider's acquisition of a cancer screening test developer, which culminated in a landmark Fifth Circuit ruling marking the government's first successful vertical merger challenge in decades.
David handled all aspects of investigations through every step of the FTC's merger review process and played important roles in administrative and federal court trials. Additionally, he made significant contributions to the 2023 Merger Guidelines and the recently revised Premerger Notification Form. In 2019, David received the prestigious Paul Rand Dixon Award for his exceptional contributions to the FTC's merger enforcement program.
Prior to the FTC, David was an associate at Katten for seven years, handling a broad range of antitrust and intellectual property litigation and counseling matters. He received Katten's Pro Bono Service Award for his work on a successful federal civil rights jury trial.
While in law school, David was an executive articles editor for the Chicago-Kent Law Review and a member of the Moot Court Honor Society.
Prior to law school, David was a Senior Research Technologist in the Laboratory of Developmental Neuroscience at the University of Chicago, where he conducted molecular genetics research and was a coauthor on numerous published papers.
